Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 1 Cancer Trials

Pittsburgh, Pennsylvania

Phase 1 cancer trials in Pittsburgh, PA

71 Phase 1 cancer studies are recruiting participants at sites in Pittsburgh as of November 17, 2026, according to ClinicalTrials.gov. Phase 1 Cancer Trials can help you understand your options and connect with a study team.

Call (888) 927-9038
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Pittsburgh at a glance

  • 71 studies are recruiting at a site in Pittsburgh.
  • By phase: Early Phase 1 (1), Phase 1 (29), Phase 1/2 (41).
  • By sponsor: industry (52), university, hospital or other (10), government (9).
  • By research area: Lung Cancer (24), Breast Cancer (14), Lymphoma (13), Melanoma (11), Prostate Cancer (6), Pancreatic Cancer (3).
  • Most recent update to one of these records: November 17, 2026.

Breast cancer studies recruiting in Pittsburgh

Basic details from each study's public record (the 30 most recently updated of 71). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Aktis Oncology, Inc.
    Registry record
    NCT07020117 · updated
  2. Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

    • Phase 1
    • Ages 12 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT05372640 · updated
  3. A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    NiKang Therapeutics, Inc.
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT07029399 · updated
  4. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Genmab
    Study site
    Allegheny Health Network
    Registry record
    NCT05579366 · updated
  5. Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Regor Pharmaceuticals Inc.
    Study site
    University of Pittsburgh Medical Center
    Registry record
    NCT07524322 · updated
  6. A Phase 1 Study of LNCB74 in Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    LigaChem Biosciences, Inc.
    Registry record
    NCT06774963 · updated
  7. A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Genentech, Inc.
    Study site
    UPMC - Hillman Cancer Center
    Registry record
    NCT07100106 · updated
  8. Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

    • Phase 1
    • Ages 18 and older
    • Female participants
    Sponsor
    Finn, Olivera, PhD
    Study site
    UPMC Magee Womens Hospital
    Registry record
    NCT06218303 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Pittsburgh, PA on ClinicalTrials.gov.

Lung cancer studies recruiting in Pittsburgh

  1. A Study of VET3-TGI in Patients With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    KaliVir Immunotherapeutics
    Study site
    UPMC- Hillman Cancer Center
    Registry record
    NCT06444815 · updated
  2. Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT06287775 · updated
  3. A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    TRIANA Biomedicines, Inc.
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT07491497 · updated
  4. Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT07397338 · updated
  5. Safety and Efficacy of OBX-115 in Advanced Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Obsidian Therapeutics, Inc.
    Study site
    Allegheny Research Institute (Melanoma/NSCLC)
    Registry record
    NCT06060613 · updated
  6. Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Olivera Finn
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT01720836 · updated
  7. Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT06162221 · updated
  8. A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Zai Lab (Shanghai) Co., Ltd.
    Study site
    University of Pittsburgh Hillman Cancer Center
    Registry record
    NCT06179069 · updated
  9. KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kura Oncology, Inc.
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT06026410 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Pittsburgh, PA on ClinicalTrials.gov.

Prostate cancer studies recruiting in Pittsburgh

  1. Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    Amgen
    Study site
    University of Pittsburgh Medical Center
    Registry record
    NCT04221542 · updated
  2. A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer

    • Phase 1
    • Ages 18 and older
    • Male participants
    Sponsor
    Aktis Oncology, Inc.
    Registry record
    NCT07581184 · updated
  3. Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

    • Phase 1
    • Ages 18 to 100
    • Male participants
    Sponsor
    Janux Therapeutics
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT05519449 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Pittsburgh, PA on ClinicalTrials.gov.

Melanoma studies recruiting in Pittsburgh

  1. Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    John Kirkwood
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT07631325 · updated
  2. Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT05896839 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Pittsburgh, PA on ClinicalTrials.gov.

Lymphoma studies recruiting in Pittsburgh

  1. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

    • Phase 1/2
    • Up to age 22
    • All sexes
    Sponsor
    PedAL BCU, LLC
    Study site
    Children's Hospital of Pittsburgh of UPMC
    Registry record
    NCT04726241 · updated
  2. Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Nurix Therapeutics, Inc.
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT07520006 · updated
  3. A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT06564038 · updated
  4. Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT06860594 · updated
  5. Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT07332507 · updated
  6. Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT07069699 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Pittsburgh, PA on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Pittsburgh

  1. Lead-212 PSV359 Therapy for Patients With Solid Tumors

    • Phase 1/2
    • Ages 18 to 90
    • All sexes
    Sponsor
    Perspective Therapeutics
    Study site
    University of Pittsburgh Medical Center
    Registry record
    NCT06710756 · updated
  2. Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    UPMC Hillman Cancer Center
    Registry record
    NCT07619521 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Pittsburgh, PA on ClinicalTrials.gov.

Ask about studies near Pittsburgh

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

More locations in Pennsylvania

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.

Phase 1 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-9038

or send a short form

How should we reach you?

Call